Related Experiment Videos
Validation of biopharmaceutical purification processes for virus clearance evaluation
1BioReliance Corp, Biosafety Testing Division, Rockville, MD 20850, USA. adarling@bioreliance.com
Molecular Biotechnology
|May 7, 2002
Summary
Biopharmaceutical products using animal-derived materials undergo rigorous viral safety testing. Downstream purification processes are studied to ensure final products are free from infectious viruses, safeguarding patient health.
Area of Science:
- Biopharmaceutical manufacturing
- Viral safety
- Product quality control
Background:
- Biopharmaceutical products utilizing animal-derived materials risk potential viral contamination.
- Ensuring product safety necessitates comprehensive viral clearance strategies.
Purpose of the Study:
- To outline the multi-stage testing protocols for viral safety in biopharmaceutical manufacturing.
- To highlight the importance of evaluating downstream purification's role in viral removal and inactivation.
Main Methods:
- Extensive testing of starting materials (e.g., cell banks) and raw materials.
- In-process testing at various manufacturing stages.
- Assessment of viral clearance capacity in downstream purification processes.
Main Results:
- Multiple testing points throughout manufacturing contribute to overall viral safety assurance.
- Downstream purification plays a critical role in mitigating viral risks, especially given limitations of direct testing.
Conclusions:
- A combination of rigorous testing and validated purification processes is essential for ensuring the viral safety of biopharmaceuticals.
- Evaluating purification capacity provides an additional layer of assurance for virus-free final products.